Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis

Molecular Cell

Volumn 61, Issue 5, 2016, Pages 705-719

  Li, Xinjian ^a   Jiang, Yuhui ^a,b   Meisenhelder, Jill ^c   Yang, Weiwei ^a   Hawke, David H ^a   Zheng, Yanhua ^a   Xia, Yan ^a,b   Aldape, Kenneth ^a   He, Jie ^d   Hunter, Tony ^c   Wang, Liwei ^b   Lu, Zhimin ^a,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d CANCER HOSPITAL   (China)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

B Raf; EGFR; Glycolysis; Hypoxia; K Ras; Mitochondria; PDH; PDHK1; PGK1; Phosphorylation; Tumorigenesis

Indexed keywords

GLYCOLYTIC ENZYME; LACTIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PGK1 PROTEIN; PROTEIN KINASE; PYRUVATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; PGK1 PROTEIN, HUMAN; PHOSPHOGLYCERATE KINASE; PIN1 PROTEIN, HUMAN; PIN1 PROTEIN, MOUSE; PROTEIN BINDING; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; PYRUVATE DEHYDROGENASE COMPLEX;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CITRIC ACID CYCLE; GLIOBLASTOMA; GLYCOLYSIS; ISOMERIZATION; MITOCHONDRION; PROGNOSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTON TRANSPORT; ANIMAL; CELL HYPOXIA; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CITRIC ACID CYCLE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLIOBLASTOMA; GLYCOLYSIS; HUMANS; MICE, NUDE; MITOCHONDRIA; MUTATION; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; PHOSPHOGLYCERATE KINASE; PHOSPHORYLATION; PROGNOSIS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); PYRUVATE DEHYDROGENASE COMPLEX; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84959561013     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2016.02.009     Document Type: Article

References (42)

1. Ahmad S.S., Glatzle J., Bajaeifer K., Bühler S., Lehmann T., Königsrainer I., Vollmer J.P., Sipos B., Ahmad S.S., Northoff H., et al. Phosphoglycerate kinase 1 as a promoter of metastasis in colon cancer. Int. J. Oncol. 2013, 43:586-590.
2. Ai J., Huang H., Lv X., Tang Z., Chen M., Chen T., Duan W., Sun H., Li Q., Tan R., et al. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell. Physiol. Biochem. 2011, 27:207-216.
3. Bernstein B.E., Hol W.G. Crystal structures of substrates and products bound to the phosphoglycerate kinase active site reveal the catalytic mechanism. Biochemistry 1998, 37:4429-4436.
4. Chacinska A., Koehler C.M., Milenkovic D., Lithgow T., Pfanner N. Importing mitochondrial proteins: machineries and mechanisms. Cell 2009, 138:628-644.
5. Chiarelli L.R., Morera S.M., Bianchi P., Fermo E., Zanella A., Galizzi A., Valentini G. Molecular insights on pathogenic effects of mutations causing phosphoglycerate kinase deficiency. PLoS ONE 2012, 7:e32065.
6. Duan Z., Lamendola D.E., Yusuf R.Z., Penson R.T., Preffer F.I., Seiden M.V. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res. 2002, 22:1933-1941.
7. Flockhart R.J., Armstrong J.L., Reynolds N.J., Lovat P.E. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br. J. Cancer 2009, 101:1448-1455.
8. Franovic A., Gunaratnam L., Smith K., Robert I., Patten D., Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc. Natl. Acad. Sci. USA 2007, 104:13092-13097.
9. Gao X., Wang H., Yang J.J., Liu X., Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
10. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
11. Guise C.P., Mowday A.M., Ashoorzadeh A., Yuan R., Lin W.H., Wu D.H., Smaill J.B., Patterson A.V., Ding K. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin. J. Cancer 2014, 33:80-86.
12. Hitosugi T., Fan J., Chung T.W., Lythgoe K., Wang X., Xie J., Ge Q., Gu T.L., Polakiewicz R.D., Roesel J.L., et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol. Cell 2011, 44:864-877.
13. Hosios A.M., Fiske B.P., Gui D.Y., Vander Heiden M.G. Lack of Evidence for PKM2 Protein Kinase Activity. Mol. Cell 2015, 59:850-857.
14. Hwang T.L., Liang Y., Chien K.Y., Yu J.S. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 2006, 6:2259-2272.
15. Jiang Y., Li X., Yang W., Hawke D.H., Zheng Y., Xia Y., Aldape K., Wei C., Guo F., Chen Y., Lu Z. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell 2014, 53:75-87.
16. Jiang Y., Wang Y., Wang T., Hawke D.H., Zheng Y., Li X., Zhou Q., Majumder S., Bi E., Liu D.X., et al. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells. Nat. Commun. 2014, 5:5566.
17. Jiang Y., Qian X., Shen J., Wang Y., Li X., Liu R., Xia Y., Chen Q., Peng G., Lin S.Y., Lu Z. Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat. Cell Biol. 2015, 17:1158-1168.
18. Kaplon J., Zheng L., Meissl K., Chaneton B., Selivanov V.A., Mackay G., van der Burg S.H., Verdegaal E.M., Cascante M., Shlomi T., et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013, 498:109-112.
19. Keller K.E., Doctor Z.M., Dwyer Z.W., Lee Y.S. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Mol. Cell 2014, 53:700-709.
20. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
21. Kronblad A., Hedenfalk I., Nilsson E., Påhlman S., Landberg G. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 2005, 24:6835-6841.
22. Li S., Swanson S.K., Gogol M., Florens L., Washburn M.P., Workman J.L., Suganuma T. Serine and SAM Responsive Complex SESAME Regulates Histone Modification Crosstalk by Sensing Cellular Metabolism. Mol. Cell 2015, 60:408-421.
23. Lu Z. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin. J. Cancer 2012, 31:5-7.
24. Lu Z. PKM2 functions as a histone kinase. Cell Cycle 2012, 11:4101-4102.
25. Lu Z., Hunter T. Prolyl isomerase Pin1 in cancer. Cell Res. 2014, 24:1033-1049.
26. Lu Z., Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006, 58:621-631.
27. Lv L., Xu Y.P., Zhao D., Li F.L., Wang W., Sasaki N., Jiang Y., Zhou X., Li T.T., Guan K.L., et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol. Cell 2013, 52:340-352.
28. Michelson A.M., Blake C.C., Evans S.T., Orkin S.H. Structure of the human phosphoglycerate kinase gene and the intron-mediated evolution and dispersal of the nucleotide-binding domain. Proc. Natl. Acad. Sci. USA 1985, 82:6965-6969.
29. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3:187-197.
30. Roche T.E., Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell. Mol. Life Sci. 2007, 64:830-849.
31. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
32. Tani K., Singer-Sam J., Munns M., Yoshida A. Molecular cloning and structure of an autosomal processed gene for human phosphoglycerate kinase. Gene 1985, 35:11-18.
33. Yaffe M.B., Schutkowski M., Shen M., Zhou X.Z., Stukenberg P.T., Rahfeld J.U., Xu J., Kuang J., Kirschner M.W., Fischer G., et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997, 278:1957-1960.
34. Yan H., Yang K., Xiao H., Zou Y.J., Zhang W.B., Liu H.Y. Over-expression of cofilin-1 and phosphoglycerate kinase 1 in astrocytomas involved in pathogenesis of radioresistance. CNS Neurosci. Ther. 2012, 18:729-736.
35. Yang W., Lu Z. Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett. 2013, 339:153-158.
36. Yang W., Lu Z. Pyruvate kinase M2 at a glance. J. Cell Sci. 2015, 128:1655-1660.
37. Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., Lu Z. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
38. Yang W., Xia Y., Hawke D., Li X., Liang J., Xing D., Aldape K., Hunter T., Alfred Yung W.K., Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012, 150:685-696.
39. Yang W., Zheng Y., Xia Y., Ji H., Chen X., Guo F., Lyssiotis C.A., Aldape K., Cantley L.C., Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 2012, 14:1295-1304.
40. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., Schmidt K., Willson J.K., Markowitz S., Zhou S., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
41. Zhang D., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., Koay E.S. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 2005, 4:1686-1696.
42. Zieker D., Konigsrainer I., Tritschler I., Loffler M., Beckert S., Traub F., Nieselt K., Buhler S., Weller M., Gaedcke J., et al. Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. Int. J. Cancer 2010, 126:1513-1520.